Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk
One month after the implantation of biodegradable-polymer sirolimus-eluting coronary stents, patients at high bleeding risk were randomly assigned to stop dual antiplatelet therapy or to continue it for at least 2 additional months. At 1 year, 1 month of DAPT was noninferior to the longer treatment...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2021-10, Vol.385 (18), p.1643-1655 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1655 |
|---|---|
| container_issue | 18 |
| container_start_page | 1643 |
| container_title | The New England journal of medicine |
| container_volume | 385 |
| creator | Valgimigli, Marco Frigoli, Enrico Heg, Dik Tijssen, Jan Jüni, Peter Vranckx, Pascal Ozaki, Yukio Morice, Marie-Claude Chevalier, Bernard Onuma, Yoshinobu Windecker, Stephan Tonino, Pim A.L Roffi, Marco Lesiak, Maciej Mahfoud, Felix Bartunek, Jozef Hildick-Smith, David Colombo, Antonio Stanković, Goran Iñiguez, Andrés Schultz, Carl Kornowski, Ran Ong, Paul J.L Alasnag, Mirvat Rodriguez, Alfredo E Moschovitis, Aris Laanmets, Peep Donahue, Michael Leonardi, Sergio Smits, Pieter C |
| description | One month after the implantation of biodegradable-polymer sirolimus-eluting coronary stents, patients at high bleeding risk were randomly assigned to stop dual antiplatelet therapy or to continue it for at least 2 additional months. At 1 year, 1 month of DAPT was noninferior to the longer treatment for ischemic cardiovascular events and was superior for bleeding. |
| doi_str_mv | 10.1056/NEJMoa2108749 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2566039600</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2566039600</sourcerecordid><originalsourceid>FETCH-LOGICAL-c500t-fdc4b90159813e4bc71c10a1162cdf71928380e29c7c06245c5c5aa1404d06373</originalsourceid><addsrcrecordid>eNp10MtLAzEQBvAgiq2Po1cJiOBldfLY7OZYa7WVqkXqeUmz2XbrvtxkD_3vjbQKCs4c5vLjY_gQOiNwTSAUN8-jx6daUQJxxOUe6pOQsYBzEPuoD0DjgEeS9dCRtWvwQ7g8RD3GOZckDvtodNepAg8qlzeFcqYwDs9XplXNBqvMmRbPhhOcV3imXG4qZ7FyeJwvV_i2MCbNqyV-ze37CTrIVGHN6e4eo7f70Xw4DqYvD5PhYBroEMAFWar5QgIJZUyY4QsdEU1AESKoTrOISBqzGAyVOtIgKA-1X6UIB56CYBE7Rlfb3KatPzpjXVLmVpuiUJWpO5vQUAhgUgB4evGHruuurfx3XsUR8UOFV8FW6ba2tjVZ0rR5qdpNQiD56jf51a_357vUblGa9Ed_F-rB5RaUpU0qsy7_CfoECc59og</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2587111126</pqid></control><display><type>article</type><title>Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Valgimigli, Marco ; Frigoli, Enrico ; Heg, Dik ; Tijssen, Jan ; Jüni, Peter ; Vranckx, Pascal ; Ozaki, Yukio ; Morice, Marie-Claude ; Chevalier, Bernard ; Onuma, Yoshinobu ; Windecker, Stephan ; Tonino, Pim A.L ; Roffi, Marco ; Lesiak, Maciej ; Mahfoud, Felix ; Bartunek, Jozef ; Hildick-Smith, David ; Colombo, Antonio ; Stanković, Goran ; Iñiguez, Andrés ; Schultz, Carl ; Kornowski, Ran ; Ong, Paul J.L ; Alasnag, Mirvat ; Rodriguez, Alfredo E ; Moschovitis, Aris ; Laanmets, Peep ; Donahue, Michael ; Leonardi, Sergio ; Smits, Pieter C</creator><creatorcontrib>Valgimigli, Marco ; Frigoli, Enrico ; Heg, Dik ; Tijssen, Jan ; Jüni, Peter ; Vranckx, Pascal ; Ozaki, Yukio ; Morice, Marie-Claude ; Chevalier, Bernard ; Onuma, Yoshinobu ; Windecker, Stephan ; Tonino, Pim A.L ; Roffi, Marco ; Lesiak, Maciej ; Mahfoud, Felix ; Bartunek, Jozef ; Hildick-Smith, David ; Colombo, Antonio ; Stanković, Goran ; Iñiguez, Andrés ; Schultz, Carl ; Kornowski, Ran ; Ong, Paul J.L ; Alasnag, Mirvat ; Rodriguez, Alfredo E ; Moschovitis, Aris ; Laanmets, Peep ; Donahue, Michael ; Leonardi, Sergio ; Smits, Pieter C ; MASTER DAPT Investigators</creatorcontrib><description>One month after the implantation of biodegradable-polymer sirolimus-eluting coronary stents, patients at high bleeding risk were randomly assigned to stop dual antiplatelet therapy or to continue it for at least 2 additional months. At 1 year, 1 month of DAPT was noninferior to the longer treatment for ischemic cardiovascular events and was superior for bleeding.</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa2108749</identifier><identifier>PMID: 34449185</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Acute Coronary Syndrome - complications ; Acute Coronary Syndrome - mortality ; Acute Coronary Syndrome - therapy ; Aged ; Anticoagulation ; Antiplatelet therapy ; Biodegradability ; Bleeding ; Cardiology ; Cardiovascular Diseases - mortality ; Cerebral infarction ; Consent ; Coronary Disease ; Drug delivery ; Drug Therapy, Combination ; Drug-Eluting Stents ; Female ; Heart ; Heart attacks ; Hemorrhage - chemically induced ; Humans ; Implants ; Kaplan-Meier Estimate ; Male ; Myocardial Infarction ; Myocardial Infarction - etiology ; Patients ; Percutaneous Coronary Intervention ; Platelet Aggregation Inhibitors - administration & dosage ; Platelet Aggregation Inhibitors - adverse effects ; Platelet Aggregation Inhibitors - therapeutic use ; Polymers ; Rapamycin ; Research centers ; Risk Factors ; Statistical analysis ; Stents ; Stroke ; Stroke - etiology ; Thromboembolism ; Thrombosis ; Thrombosis - prevention & control</subject><ispartof>The New England journal of medicine, 2021-10, Vol.385 (18), p.1643-1655</ispartof><rights>Copyright © 2021 Massachusetts Medical Society. All rights reserved.</rights><rights>Copyright © 2021 Massachusetts Medical Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c500t-fdc4b90159813e4bc71c10a1162cdf71928380e29c7c06245c5c5aa1404d06373</citedby><cites>FETCH-LOGICAL-c500t-fdc4b90159813e4bc71c10a1162cdf71928380e29c7c06245c5c5aa1404d06373</cites><orcidid>0000-0002-4353-7110</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa2108749$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2587111126?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,777,781,2746,2747,26084,27905,27906,52363,54045,64364,64366,64368,72218</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34449185$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Valgimigli, Marco</creatorcontrib><creatorcontrib>Frigoli, Enrico</creatorcontrib><creatorcontrib>Heg, Dik</creatorcontrib><creatorcontrib>Tijssen, Jan</creatorcontrib><creatorcontrib>Jüni, Peter</creatorcontrib><creatorcontrib>Vranckx, Pascal</creatorcontrib><creatorcontrib>Ozaki, Yukio</creatorcontrib><creatorcontrib>Morice, Marie-Claude</creatorcontrib><creatorcontrib>Chevalier, Bernard</creatorcontrib><creatorcontrib>Onuma, Yoshinobu</creatorcontrib><creatorcontrib>Windecker, Stephan</creatorcontrib><creatorcontrib>Tonino, Pim A.L</creatorcontrib><creatorcontrib>Roffi, Marco</creatorcontrib><creatorcontrib>Lesiak, Maciej</creatorcontrib><creatorcontrib>Mahfoud, Felix</creatorcontrib><creatorcontrib>Bartunek, Jozef</creatorcontrib><creatorcontrib>Hildick-Smith, David</creatorcontrib><creatorcontrib>Colombo, Antonio</creatorcontrib><creatorcontrib>Stanković, Goran</creatorcontrib><creatorcontrib>Iñiguez, Andrés</creatorcontrib><creatorcontrib>Schultz, Carl</creatorcontrib><creatorcontrib>Kornowski, Ran</creatorcontrib><creatorcontrib>Ong, Paul J.L</creatorcontrib><creatorcontrib>Alasnag, Mirvat</creatorcontrib><creatorcontrib>Rodriguez, Alfredo E</creatorcontrib><creatorcontrib>Moschovitis, Aris</creatorcontrib><creatorcontrib>Laanmets, Peep</creatorcontrib><creatorcontrib>Donahue, Michael</creatorcontrib><creatorcontrib>Leonardi, Sergio</creatorcontrib><creatorcontrib>Smits, Pieter C</creatorcontrib><creatorcontrib>MASTER DAPT Investigators</creatorcontrib><title>Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>One month after the implantation of biodegradable-polymer sirolimus-eluting coronary stents, patients at high bleeding risk were randomly assigned to stop dual antiplatelet therapy or to continue it for at least 2 additional months. At 1 year, 1 month of DAPT was noninferior to the longer treatment for ischemic cardiovascular events and was superior for bleeding.</description><subject>Acute Coronary Syndrome - complications</subject><subject>Acute Coronary Syndrome - mortality</subject><subject>Acute Coronary Syndrome - therapy</subject><subject>Aged</subject><subject>Anticoagulation</subject><subject>Antiplatelet therapy</subject><subject>Biodegradability</subject><subject>Bleeding</subject><subject>Cardiology</subject><subject>Cardiovascular Diseases - mortality</subject><subject>Cerebral infarction</subject><subject>Consent</subject><subject>Coronary Disease</subject><subject>Drug delivery</subject><subject>Drug Therapy, Combination</subject><subject>Drug-Eluting Stents</subject><subject>Female</subject><subject>Heart</subject><subject>Heart attacks</subject><subject>Hemorrhage - chemically induced</subject><subject>Humans</subject><subject>Implants</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Myocardial Infarction</subject><subject>Myocardial Infarction - etiology</subject><subject>Patients</subject><subject>Percutaneous Coronary Intervention</subject><subject>Platelet Aggregation Inhibitors - administration & dosage</subject><subject>Platelet Aggregation Inhibitors - adverse effects</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Polymers</subject><subject>Rapamycin</subject><subject>Research centers</subject><subject>Risk Factors</subject><subject>Statistical analysis</subject><subject>Stents</subject><subject>Stroke</subject><subject>Stroke - etiology</subject><subject>Thromboembolism</subject><subject>Thrombosis</subject><subject>Thrombosis - prevention & control</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp10MtLAzEQBvAgiq2Po1cJiOBldfLY7OZYa7WVqkXqeUmz2XbrvtxkD_3vjbQKCs4c5vLjY_gQOiNwTSAUN8-jx6daUQJxxOUe6pOQsYBzEPuoD0DjgEeS9dCRtWvwQ7g8RD3GOZckDvtodNepAg8qlzeFcqYwDs9XplXNBqvMmRbPhhOcV3imXG4qZ7FyeJwvV_i2MCbNqyV-ze37CTrIVGHN6e4eo7f70Xw4DqYvD5PhYBroEMAFWar5QgIJZUyY4QsdEU1AESKoTrOISBqzGAyVOtIgKA-1X6UIB56CYBE7Rlfb3KatPzpjXVLmVpuiUJWpO5vQUAhgUgB4evGHruuurfx3XsUR8UOFV8FW6ba2tjVZ0rR5qdpNQiD56jf51a_357vUblGa9Ed_F-rB5RaUpU0qsy7_CfoECc59og</recordid><startdate>20211028</startdate><enddate>20211028</enddate><creator>Valgimigli, Marco</creator><creator>Frigoli, Enrico</creator><creator>Heg, Dik</creator><creator>Tijssen, Jan</creator><creator>Jüni, Peter</creator><creator>Vranckx, Pascal</creator><creator>Ozaki, Yukio</creator><creator>Morice, Marie-Claude</creator><creator>Chevalier, Bernard</creator><creator>Onuma, Yoshinobu</creator><creator>Windecker, Stephan</creator><creator>Tonino, Pim A.L</creator><creator>Roffi, Marco</creator><creator>Lesiak, Maciej</creator><creator>Mahfoud, Felix</creator><creator>Bartunek, Jozef</creator><creator>Hildick-Smith, David</creator><creator>Colombo, Antonio</creator><creator>Stanković, Goran</creator><creator>Iñiguez, Andrés</creator><creator>Schultz, Carl</creator><creator>Kornowski, Ran</creator><creator>Ong, Paul J.L</creator><creator>Alasnag, Mirvat</creator><creator>Rodriguez, Alfredo E</creator><creator>Moschovitis, Aris</creator><creator>Laanmets, Peep</creator><creator>Donahue, Michael</creator><creator>Leonardi, Sergio</creator><creator>Smits, Pieter C</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4353-7110</orcidid></search><sort><creationdate>20211028</creationdate><title>Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk</title><author>Valgimigli, Marco ; Frigoli, Enrico ; Heg, Dik ; Tijssen, Jan ; Jüni, Peter ; Vranckx, Pascal ; Ozaki, Yukio ; Morice, Marie-Claude ; Chevalier, Bernard ; Onuma, Yoshinobu ; Windecker, Stephan ; Tonino, Pim A.L ; Roffi, Marco ; Lesiak, Maciej ; Mahfoud, Felix ; Bartunek, Jozef ; Hildick-Smith, David ; Colombo, Antonio ; Stanković, Goran ; Iñiguez, Andrés ; Schultz, Carl ; Kornowski, Ran ; Ong, Paul J.L ; Alasnag, Mirvat ; Rodriguez, Alfredo E ; Moschovitis, Aris ; Laanmets, Peep ; Donahue, Michael ; Leonardi, Sergio ; Smits, Pieter C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c500t-fdc4b90159813e4bc71c10a1162cdf71928380e29c7c06245c5c5aa1404d06373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acute Coronary Syndrome - complications</topic><topic>Acute Coronary Syndrome - mortality</topic><topic>Acute Coronary Syndrome - therapy</topic><topic>Aged</topic><topic>Anticoagulation</topic><topic>Antiplatelet therapy</topic><topic>Biodegradability</topic><topic>Bleeding</topic><topic>Cardiology</topic><topic>Cardiovascular Diseases - mortality</topic><topic>Cerebral infarction</topic><topic>Consent</topic><topic>Coronary Disease</topic><topic>Drug delivery</topic><topic>Drug Therapy, Combination</topic><topic>Drug-Eluting Stents</topic><topic>Female</topic><topic>Heart</topic><topic>Heart attacks</topic><topic>Hemorrhage - chemically induced</topic><topic>Humans</topic><topic>Implants</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Myocardial Infarction</topic><topic>Myocardial Infarction - etiology</topic><topic>Patients</topic><topic>Percutaneous Coronary Intervention</topic><topic>Platelet Aggregation Inhibitors - administration & dosage</topic><topic>Platelet Aggregation Inhibitors - adverse effects</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Polymers</topic><topic>Rapamycin</topic><topic>Research centers</topic><topic>Risk Factors</topic><topic>Statistical analysis</topic><topic>Stents</topic><topic>Stroke</topic><topic>Stroke - etiology</topic><topic>Thromboembolism</topic><topic>Thrombosis</topic><topic>Thrombosis - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Valgimigli, Marco</creatorcontrib><creatorcontrib>Frigoli, Enrico</creatorcontrib><creatorcontrib>Heg, Dik</creatorcontrib><creatorcontrib>Tijssen, Jan</creatorcontrib><creatorcontrib>Jüni, Peter</creatorcontrib><creatorcontrib>Vranckx, Pascal</creatorcontrib><creatorcontrib>Ozaki, Yukio</creatorcontrib><creatorcontrib>Morice, Marie-Claude</creatorcontrib><creatorcontrib>Chevalier, Bernard</creatorcontrib><creatorcontrib>Onuma, Yoshinobu</creatorcontrib><creatorcontrib>Windecker, Stephan</creatorcontrib><creatorcontrib>Tonino, Pim A.L</creatorcontrib><creatorcontrib>Roffi, Marco</creatorcontrib><creatorcontrib>Lesiak, Maciej</creatorcontrib><creatorcontrib>Mahfoud, Felix</creatorcontrib><creatorcontrib>Bartunek, Jozef</creatorcontrib><creatorcontrib>Hildick-Smith, David</creatorcontrib><creatorcontrib>Colombo, Antonio</creatorcontrib><creatorcontrib>Stanković, Goran</creatorcontrib><creatorcontrib>Iñiguez, Andrés</creatorcontrib><creatorcontrib>Schultz, Carl</creatorcontrib><creatorcontrib>Kornowski, Ran</creatorcontrib><creatorcontrib>Ong, Paul J.L</creatorcontrib><creatorcontrib>Alasnag, Mirvat</creatorcontrib><creatorcontrib>Rodriguez, Alfredo E</creatorcontrib><creatorcontrib>Moschovitis, Aris</creatorcontrib><creatorcontrib>Laanmets, Peep</creatorcontrib><creatorcontrib>Donahue, Michael</creatorcontrib><creatorcontrib>Leonardi, Sergio</creatorcontrib><creatorcontrib>Smits, Pieter C</creatorcontrib><creatorcontrib>MASTER DAPT Investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Valgimigli, Marco</au><au>Frigoli, Enrico</au><au>Heg, Dik</au><au>Tijssen, Jan</au><au>Jüni, Peter</au><au>Vranckx, Pascal</au><au>Ozaki, Yukio</au><au>Morice, Marie-Claude</au><au>Chevalier, Bernard</au><au>Onuma, Yoshinobu</au><au>Windecker, Stephan</au><au>Tonino, Pim A.L</au><au>Roffi, Marco</au><au>Lesiak, Maciej</au><au>Mahfoud, Felix</au><au>Bartunek, Jozef</au><au>Hildick-Smith, David</au><au>Colombo, Antonio</au><au>Stanković, Goran</au><au>Iñiguez, Andrés</au><au>Schultz, Carl</au><au>Kornowski, Ran</au><au>Ong, Paul J.L</au><au>Alasnag, Mirvat</au><au>Rodriguez, Alfredo E</au><au>Moschovitis, Aris</au><au>Laanmets, Peep</au><au>Donahue, Michael</au><au>Leonardi, Sergio</au><au>Smits, Pieter C</au><aucorp>MASTER DAPT Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2021-10-28</date><risdate>2021</risdate><volume>385</volume><issue>18</issue><spage>1643</spage><epage>1655</epage><pages>1643-1655</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>One month after the implantation of biodegradable-polymer sirolimus-eluting coronary stents, patients at high bleeding risk were randomly assigned to stop dual antiplatelet therapy or to continue it for at least 2 additional months. At 1 year, 1 month of DAPT was noninferior to the longer treatment for ischemic cardiovascular events and was superior for bleeding.</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>34449185</pmid><doi>10.1056/NEJMoa2108749</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-4353-7110</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2021-10, Vol.385 (18), p.1643-1655 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2566039600 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Acute Coronary Syndrome - complications Acute Coronary Syndrome - mortality Acute Coronary Syndrome - therapy Aged Anticoagulation Antiplatelet therapy Biodegradability Bleeding Cardiology Cardiovascular Diseases - mortality Cerebral infarction Consent Coronary Disease Drug delivery Drug Therapy, Combination Drug-Eluting Stents Female Heart Heart attacks Hemorrhage - chemically induced Humans Implants Kaplan-Meier Estimate Male Myocardial Infarction Myocardial Infarction - etiology Patients Percutaneous Coronary Intervention Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use Polymers Rapamycin Research centers Risk Factors Statistical analysis Stents Stroke Stroke - etiology Thromboembolism Thrombosis Thrombosis - prevention & control |
| title | Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T10%3A11%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dual%20Antiplatelet%20Therapy%20after%20PCI%20in%20Patients%20at%20High%20Bleeding%20Risk&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Valgimigli,%20Marco&rft.aucorp=MASTER%20DAPT%20Investigators&rft.date=2021-10-28&rft.volume=385&rft.issue=18&rft.spage=1643&rft.epage=1655&rft.pages=1643-1655&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMoa2108749&rft_dat=%3Cproquest_cross%3E2566039600%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2587111126&rft_id=info:pmid/34449185&rfr_iscdi=true |